← All trials
NCT05830799
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 29, 2023
- Primary completion
- May 11, 2023
- Completion date
- May 11, 2023
- First posted
- Apr 26, 2023
- Last posted
- Jun 1, 2023
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vicore Pharma ABLead sponsor
- Clinical Trial Consultants ABOverall official - principal investigator
- Clinical Trial Consultants ABStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.